We did not find any significant association between acquired ESR1 alterations (mutations, amplifications), or mutations in other BC-related genes, and the administration of adjuvant chemotherapy, which occurred in 43% of patients included in our study cohort (mostly anthracycline-containing regimens). Here, ESR1 is linked to breast cancer.